A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1609-1617

  Adachi, Kyoichi ^a   Furuta, Kenji ^a   Miwa, Hiroto ^b   Oshima, Tadayuki ^b   Miki, Masaharu ^c   Komazawa, Yoshinori ^d   Iwakiri, Katsuhiko ^e   Furuta, Takahisa ^f   Koike, Tomoyuki ^g   Shimatani, Tomohiko ^h   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^d Izumo City General Medical Center   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

GERD; GSRS; NERD; PPI; QUEST

Indexed keywords

LANSOPRAZOLE; PROTON PUMP INHIBITOR; REBAMIPIDE;

ABDOMINAL PAIN; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON EROSIVE REFLUX DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUINOLONES; RECURRENCE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864287360     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2087-6     Document Type: Article

References (47)

1. Dodds WJ, Hogan WJ, Helm JF, Dent J. Pathogenesis of reflux esophagitis. Gastroenterology. 1981;81:376-394. (Pubitemid 11093172)
2. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086-2100.
3. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol. 2001;96: 303-314.
4. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther. 2000;14:1589-1594. (Pubitemid 32011732)
5. Furukawa N, Iwakiri R, Koyama T, et al. Proportion of reflux esophagitis in 6,010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol. 1999;3:441-444. (Pubitemid 29408167)
6. Amano K, Adachi K, Katsube T, Watanabe M, Kinoshita Y. Roleof hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol. 2001;16:132-136. (Pubitemid 32226183)
7. Mishima I, Adachi K, Arima N, et al. Prevalence of endoscopi-cally negative and positive gastroesophageal reflux disease in the Japanese. Scand J Gastroenterol. 2005;40:1005-1009. (Pubitemid 41291347)
8. Moki F, Kusano M, Mizuide M, et al. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther. 2007;26:1069-1075. (Pubitemid 47416298)
9. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398-407.
10. Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol. 1993;28:18-21. (Pubitemid 24084823)
11. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II-IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810. (Pubitemid 27240763)
12. Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther. 1997;11:755-763. (Pubitemid 27376365)
13. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32: 974-979. (Pubitemid 27433659)
14. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656-664. (Pubitemid 39013424)
15. Miwa H, Sasaki M, Furuta T, et al. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26:69-77. (Pubitemid 46889840)
16. Lee ES, Kim N, Lee SH, et al. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30:154-164.
17. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987;142:23-29. (Pubitemid 17159903)
18. Ogino K, Hobara T, Ishiyama H, et al. Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyl-dithiocarbamate-induced antral gastric ulcers in rats. Eur J Pharmacol. 1992;212:9-13.
19. Sun WH, Tsuji S, Tsujii M, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295:447-452.
20. Suetsugu H, Ishihara S, Moriyama N, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136:50-57.
21. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamip-ide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S-13S. (Pubitemid 28433943)
22. Park SH, Cho CS, Lee OY, et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial - STORM STUDY. J Clin Biochem Nutr. 2007;40:148-155.
23. Suzuki M, Miura S, Mori M, et al. Rebamipide, a novel anti-ulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut. 1994;35:1375-1378. (Pubitemid 24310895)
24. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363-366. (Pubitemid 23093246)
25. Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med. 1995;18: 117-123.
26. Aihara M, Azuma A, Takizawa H, et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Heli-cobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci. 1998;43:174S-180S. (Pubitemid 28433969)
27. Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci. 2005;50: S97-S103. (Pubitemid 41380805)
28. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55:3393-3398.
29. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastro-esophageal reflux disease. Scand J Gastroenterol. 1998;33: 1023-1029. (Pubitemid 28505643)
30. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7: 75-83. (Pubitemid 28113967)
31. Miwa H, Osada T, Nagahara A, et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double blind placebo-controlled study in Japan. J Gastroenterol Hepatol. 2006;21:1826-1831. (Pubitemid 44657004)
32. Talley NJ, Riff DS, Schwartz H, Marcuard SP. Double-blind placebo-controlled multicentre studies of rebamipide. Aliment Pharmacol Ther. 2001;15:1603-1611.
33. Wu JC, Cheung CM, Wong VW, Sung JJ. Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:690-695. (Pubitemid 46830055)
34. Adachi K, Matsumori Y, Fujisawa T, et al. Symptomatic diversity of patients with reflux esophagitis: effect of omeprazole treatment. J Clin Biochem Nutr. 2006;39:46-54. (Pubitemid 44201982)
35. Noh YW, Jung HK, Kim SE, Jung SA. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16:148-156.
36. Rodriguez-Stanley S, Robinson M, Earnest DL, Greenwood-Van Meerveld B, Miner PB Jr. Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol. 1999;94:628-631. (Pubitemid 29124857)
37. Nagahara A, Miwa H, Minoo T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40: 891-895. (Pubitemid 44690761)
38. Miwa H, Minoo T, Hojo M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastrooesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20:112-117. (Pubitemid 39120282)
39. Balaban DH, Yamamoto Y, Liu J, et al. Sustained esophageal con-traction:a markerofesophageal chest pain identifiedbyintraluminal ultrasonography. Gastroenterology. 1999;116:29-37. (Pubitemid 29013490)
40. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol. 2001;281:G743-G751.
41. Wiklund I, Carlsson R, Carlsson J, Glise H. Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials. Scand J Gastroenterol. 2006; 41:288-293.
42. Richter JE, Kovacs TO, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 1999;13:795-804. (Pubitemid 29276850)
43. Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med. 2000;160:1803-1809. (Pubitemid 30418818)
44. Hiyama T, Matsuo K, Urabe Y, et al. Meta-analysis used to identify factors associated with the. J Gastroenterol Hepatol. 2009;24:1326-1332.
45. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effects of omeprazole in patients with duodenal ulcer. Gastroenterology. 1996;110:725-732. (Pubitemid 26071839)
46. Gillen D, Wirz AA, Neithercut WD, Ardill JE, McColl KE. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut. 1999;44:468-475. (Pubitemid 29169945)
47. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther. 2000;14:1049-1056. (Pubitemid 30618166)